| James Heath Miller, MD | |
|
4245 Roosevelt Way Ne, Seattle, WA 98105 | |
| (206) 520-5000 | |
| Not Available |
| Full Name | James Heath Miller |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 4245 Roosevelt Way Ne, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447246731 | NPI | - | NPPES |
| 1447246731 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD00033236 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Washington Medical Ctr | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Association Of University Physicians | 0446162697 | 3009 |
News Archive
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime. Limiting exposure to ultraviolet radiation is the number one way individuals can reduce their risk of skin cancer, though new data suggests that UV exposure is on the rise, particularly among Caucasian girls and young women.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
House Speaker Nancy Pelosi is "confident" she will be able to get the votes needed to pass health care reform, "even if it threatens the political careers of some members of her party," The New York Times reports.
› Verified 3 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime. Limiting exposure to ultraviolet radiation is the number one way individuals can reduce their risk of skin cancer, though new data suggests that UV exposure is on the rise, particularly among Caucasian girls and young women.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
House Speaker Nancy Pelosi is "confident" she will be able to get the votes needed to pass health care reform, "even if it threatens the political careers of some members of her party," The New York Times reports.
› Verified 3 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime. Limiting exposure to ultraviolet radiation is the number one way individuals can reduce their risk of skin cancer, though new data suggests that UV exposure is on the rise, particularly among Caucasian girls and young women.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
House Speaker Nancy Pelosi is "confident" she will be able to get the votes needed to pass health care reform, "even if it threatens the political careers of some members of her party," The New York Times reports.
› Verified 3 days ago
| Entity Name | Obstetrix Medical Group Of Washington Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861599573 PECOS PAC ID: 3577451947 Enrollment ID: O20040308000679 |
News Archive
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime. Limiting exposure to ultraviolet radiation is the number one way individuals can reduce their risk of skin cancer, though new data suggests that UV exposure is on the rise, particularly among Caucasian girls and young women.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
House Speaker Nancy Pelosi is "confident" she will be able to get the votes needed to pass health care reform, "even if it threatens the political careers of some members of her party," The New York Times reports.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Heath Miller, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | James Heath Miller, MD 4245 Roosevelt Way Ne, Seattle, WA 98105 Ph: (206) 520-5000 |
News Archive
According to a new study published in The Lancet Haematology, recombinant human erythropoietin (rHuEPO), a performance augmenting drug has little effects on high-intensity laboratory cycling test among well-trained amateur cyclists; yet in the laboratory time trial test and endurance road-race up Mont Ventoux (France), the augmenting effects were typically undetectable.
Skin cancer is the most common cancer in the U.S., affecting one in five Americans in their lifetime. Limiting exposure to ultraviolet radiation is the number one way individuals can reduce their risk of skin cancer, though new data suggests that UV exposure is on the rise, particularly among Caucasian girls and young women.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
House Speaker Nancy Pelosi is "confident" she will be able to get the votes needed to pass health care reform, "even if it threatens the political careers of some members of her party," The New York Times reports.
› Verified 3 days ago
Dr. Jaime Marie Michaelson, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 310 15th Ave E, Seattle, WA 98112 Phone: 206-326-3000 | |
Alisa Beth Kachikis, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St, 3rd Floor Sw 350, Seattle, WA 98195 Phone: 206-598-4070 | |
Karen L. Bohmke, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1101 Madison St, #1150, Seattle, WA 98104 Phone: 206-386-3400 | |
Lisa S. Callegari, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 | |
Anne-marie Elizabeth Amies Oelschlager, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Uwmc-roosevelt, 4245 Roosevelt Way Ne, Seattle, WA 98105 Phone: 206-598-5500 | |
Shirley Andrews, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1560 N 115th St Ste 212, Seattle, WA 98133 Phone: 206-363-2800 Fax: 206-363-2811 | |
Lyndsey Summer Benson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Box 356460, Seattle, WA 98195 Phone: 610-202-4028 |